
Chinese General Practice ›› 2026, Vol. 29 ›› Issue (33): 4960-4972.DOI: 10.12114/j.issn.1007-9572.2025.0363
• Evidence-based Medicine • Previous Articles Next Articles
Received:2025-11-10
Revised:2026-01-14
Published:2026-11-20
Online:2026-10-21
Contact:
LI Jun
通讯作者:
李军
作者简介:作者贡献:
满逸迪负责确定研究思路,研究计划、执行的管理和协调,获取数据,分析或解释数据,起草、撰写、修改研究论文;李思慧负责确定研究思路或设计,协助收集整理数据,协助修改论文;王芹负责对重要的知识内容进行审查、修订,最终定稿,筹措、提供研究资金;李军确定研究思路,对研究工作全面负责。
基金资助:CLC Number:
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.chinagp.net/EN/10.12114/j.issn.1007-9572.2025.0363
| 步骤 | 检索式 |
|---|---|
| #1 | cerebral injury [Mesh] |
| #2 | cerebral trauma [Title/Abstract] |
| #3 | cerebrovascular accodent [Title/Abstract] |
| #4 | #1 OR #2 OR #3 |
| #5 | consciousness disorder [Mesh] |
| #6 | coma [Title/Abstract] |
| #7 | minimally conscious state [Title/Abstract] |
| #8 | vegetative state [Title/Abstract] |
| #9 | unresponsive wakefulness syndrome [Title/Abstract] |
| #10 | #5 OR #6 OR #7 OR #8 OR #9 |
| #11 | Invasive Brain Stimulation [Mesh] |
| #12 | Transcranial Magnetic Stimulation [Title/Abstract] |
| #13 | rTMS [Title/Abstract] |
| #14 | transcranial direct current stimulation [Title/Abstract] |
| #15 | tDCs [Title/Abstract] |
| #16 | theta burst stimulation [Title/Abstract] |
| #17 | TBS [Title/Abstract] |
| #18 | Peripheral nerve electrical stimulation [Title/Abstract] |
| #19 | #11 OR #12 OR #13 OR #14 OR #15 #16 OR #17 OR #18 |
| #20 | #4 AND #10 AND #19 |
Table 1 PubMed database search strategy
| 步骤 | 检索式 |
|---|---|
| #1 | cerebral injury [Mesh] |
| #2 | cerebral trauma [Title/Abstract] |
| #3 | cerebrovascular accodent [Title/Abstract] |
| #4 | #1 OR #2 OR #3 |
| #5 | consciousness disorder [Mesh] |
| #6 | coma [Title/Abstract] |
| #7 | minimally conscious state [Title/Abstract] |
| #8 | vegetative state [Title/Abstract] |
| #9 | unresponsive wakefulness syndrome [Title/Abstract] |
| #10 | #5 OR #6 OR #7 OR #8 OR #9 |
| #11 | Invasive Brain Stimulation [Mesh] |
| #12 | Transcranial Magnetic Stimulation [Title/Abstract] |
| #13 | rTMS [Title/Abstract] |
| #14 | transcranial direct current stimulation [Title/Abstract] |
| #15 | tDCs [Title/Abstract] |
| #16 | theta burst stimulation [Title/Abstract] |
| #17 | TBS [Title/Abstract] |
| #18 | Peripheral nerve electrical stimulation [Title/Abstract] |
| #19 | #11 OR #12 OR #13 OR #14 OR #15 #16 OR #17 OR #18 |
| #20 | #4 AND #10 AND #19 |
| 第一作者 | 时间(年) | 国家 | 样本量(T/C)(例) | 平均年龄(T/C) ( | 平均病程(T/C) | 干预措施(T/C) | 刺激部位 | 刺激强度 | 刺激频率(Hz) | 干预时间 | 结局指标 | 随访时间 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cavinato[ | 2019 | 意大利 | 12/12 | 47.00±17.00/ 53.00±19.00 | (32.00±31)d/(47.00±45)d | tDCS+常规治疗/假刺激+常规治疗 | DLPFC | 2 mA | — | 10 d | CRS-R | — |
| Chen[ | 2022 | 中国 | 25/25 | 50.52±13.85/ 52.60±14.39 | (2.28±1.57)m/(2±1.57)m | HF-rTMS+常规治疗/假刺激+常规治疗 | DLPFC | 90%RMT | 10 | 6 w | CRS-R、GCS | — |
| Chen[ | 2025 | 中国 | 23/21 | 55.10±15.40/ 48.28±22.26 | — | iTBS+常规治疗/假刺激+常规治疗 | CR | 90%RMT | 5 | 5 d | CRS-R | 6 m |
| Estraneo[ | 2017 | 意大利 | 8/5 | — | — | tDCS+常规治疗/假刺激+常规治疗 | DLPFC | 2 mA | — | 1 w | CRS-R | |
| Fan[ | 2022 | 中国 | 20/20 | — | — | HF-rTMS+常规治疗/假刺激+常规治疗 | DLPFC | 100%RMT | 20 | 4 w | CRS-R | — |
| He[ | 2021 | 中国 | 25/25 | 51.00±2.30/ 53.10±2.30 | (85.9±20.7)d/(86.2±12.7)d | HF-rTMS+常规治疗/假刺激+常规治疗 | 左侧DLPFC | 100%RMT | 10 | 2 w | CRS-R | — |
| Li[ | 2024 | 中国 | 10/10 | 41.60±17.60/ 54.80±20.80 | (3.35±3.16)m/(3.70±2.50)m | HF-rTMS+常规治疗/假刺激+常规治疗 | PL | 90%RMT | 10 | 2 w | CRS-R | — |
| Liu[ | 2025 | 中国 | 24/24 | 52.20±15.80/ 56.00± 16.6 | (66.00±40.03)d/(64.11±30.49)d | HF-rTMS+常规治疗/常规治疗 | DLPFC | 90%RMT | 10 | 4 w | GCS | |
| Martens[ | 2020 | 加拿大 | 26/20 | — | — | tDCS+常规治疗/假刺激+常规治疗 | FL+PL | 4 mA | — | 6 d | CRS-R | — |
| Nekkanti[ | 2016 | 马来西亚 | 10/10 | — | — | MNES+常规治疗/常规治疗 | 正中神经 | 20 mA | 40 | 1 m | GCS | 1 m |
| Sun[ | 2023 | 中国 | 39/39 | 56.49±8.56/ 55.33±9.63 | (22.12±8.35)d/(21.85±7.41)d | tDCS+常规治疗/常规治疗 | DLPFC | 2 mA | — | 8 w | GCS | 8 w |
| Thibaut[ | 2023 | 比利时 | 33/29 | — | — | tDCS+常规治疗/假刺激+常规治疗 | DLPFC | 2 mA | — | 4 w | CRS-R | — |
| Xu[ | 2023 | 中国 | 10/10 | — | — | HF-rTMS+常规治疗/假刺激+常规治疗 | PPC | 90%RMT | 10 | 10 d | CRS-R | — |
| Xu[ | 2024 | 中国 | 10/10 | — | — | HF-rTMS+常规治疗/假刺激+常规治疗 | DLPFC | 90%RMT | 10 | 10 d | CRS-R | — |
| Zhou[ | 2023 | 中国 | 25/25 | 54.03±12.18/ 53.74±12.10 | (55.15±44.81)d/(39.55±23.97)d | ta-VNS+常规治疗/假刺激+常规治疗 | 左耳耳屏 | — | 20 | 4 w | CRS-R、GCS | 8 w |
| 曾淑娟[ | 2023 | 中国 | 22/20 | 43.14±2.81/ 43.60±3.07 | (5.25±0.51)m/(5.12±0.52)m | HF-rTMS+药物治疗/假刺激+药物治疗 | TPJ | 100%RMT | 10 | 2 w | CRS-R | — |
| 陈擘璨[ | 2021 | 中国 | 80/80 | 56.16±10.56/ 54.25±10.30 | (5.33±2.40)m/(5.44±2.16)m | HF-rTMS+常规治疗/常规治疗 | DLPFC | 80%RMT | 20 | 3 m | GCS | — |
| 陈冬艳[ | 2024 | 中国 | 44/44 | — | — | HF-rTMS+常规治疗/常规治疗 | DLPFC | 110%RMT | 5 | 4 w | CRS-R、GCS | — |
| 陈荣[ | 2014 | 中国 | 30/30 | 61.73±5.07/ 60.90±4.72 | — | MNES+常规治疗/常规治疗 | 正中神经 | 15~20 mA | 50~150 | 4 w | GCS | — |
| 程晓午[ | 2021 | 中国 | 30/30 | 52.11±8.50/ 52.03±8.93 | (4.3±1.6)m/(4.3±1.5)m | MNES+常规治疗/常规治疗 | 正中神经 | 10~20 mA | 40 | 21 d | GCS | — |
| 程杨玉[ | 2023 | 中国 | 61/61 | 39.57±9.51/ 40.49±9.26 | — | MNES+常规治疗/常规治疗 | 正中神经 | — | 40 | 10 d | GCS | — |
| 池林[ | 2018 | 中国 | 19/19 | 42.68±14.81/ 45.37±13.04 | (29.63±4.69)d/(27.42±4.69)d | tDCS+常规治疗/常规治疗 | DLPFC | 2 mA | — | 20 d | GCS | — |
| 丁锦荣[ | 2018 | 中国 | 50/50 | — | — | MNES+常规治疗/常规治疗 | 正中神经点 | 20 mA | 40 | 3 m | GCS | — |
| 封苏平[ | 2008 | 中国 | 20/20 | 36.12±10.31/ 34.56±9.33 | — | MNES+常规治疗/常规治疗 | 正中神经点 | 20 mA | 40 | 4 w | GCS | — |
| 冯枫[ | 2020 | 中国 | 25/25 | 50.75±4.51/ 51.23±4.77 | — | tDCS+常规治疗/常规治疗 | DLPFC | 1~2 mA | — | 40 d | CRS-R | |
| 郭静[ | 2021 | 中国 | 57/56 | 45.12±4.22/ 44.71±4.63 | — | tDCS+常规治疗/常规治疗 | DLPFC | 1.4 mA | — | 4 w | GCS | — |
| 洪盈盈[ | 2022 | 中国 | 40/39 | 52.69±3.64/ 52.47±3.58 | — | tDCS+常规治疗/常规治疗 | DLPFC | 1~2 mA | — | 20 d | CRS-R | — |
Table 2 Basic characteristics of included literature
| 第一作者 | 时间(年) | 国家 | 样本量(T/C)(例) | 平均年龄(T/C) ( | 平均病程(T/C) | 干预措施(T/C) | 刺激部位 | 刺激强度 | 刺激频率(Hz) | 干预时间 | 结局指标 | 随访时间 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cavinato[ | 2019 | 意大利 | 12/12 | 47.00±17.00/ 53.00±19.00 | (32.00±31)d/(47.00±45)d | tDCS+常规治疗/假刺激+常规治疗 | DLPFC | 2 mA | — | 10 d | CRS-R | — |
| Chen[ | 2022 | 中国 | 25/25 | 50.52±13.85/ 52.60±14.39 | (2.28±1.57)m/(2±1.57)m | HF-rTMS+常规治疗/假刺激+常规治疗 | DLPFC | 90%RMT | 10 | 6 w | CRS-R、GCS | — |
| Chen[ | 2025 | 中国 | 23/21 | 55.10±15.40/ 48.28±22.26 | — | iTBS+常规治疗/假刺激+常规治疗 | CR | 90%RMT | 5 | 5 d | CRS-R | 6 m |
| Estraneo[ | 2017 | 意大利 | 8/5 | — | — | tDCS+常规治疗/假刺激+常规治疗 | DLPFC | 2 mA | — | 1 w | CRS-R | |
| Fan[ | 2022 | 中国 | 20/20 | — | — | HF-rTMS+常规治疗/假刺激+常规治疗 | DLPFC | 100%RMT | 20 | 4 w | CRS-R | — |
| He[ | 2021 | 中国 | 25/25 | 51.00±2.30/ 53.10±2.30 | (85.9±20.7)d/(86.2±12.7)d | HF-rTMS+常规治疗/假刺激+常规治疗 | 左侧DLPFC | 100%RMT | 10 | 2 w | CRS-R | — |
| Li[ | 2024 | 中国 | 10/10 | 41.60±17.60/ 54.80±20.80 | (3.35±3.16)m/(3.70±2.50)m | HF-rTMS+常规治疗/假刺激+常规治疗 | PL | 90%RMT | 10 | 2 w | CRS-R | — |
| Liu[ | 2025 | 中国 | 24/24 | 52.20±15.80/ 56.00± 16.6 | (66.00±40.03)d/(64.11±30.49)d | HF-rTMS+常规治疗/常规治疗 | DLPFC | 90%RMT | 10 | 4 w | GCS | |
| Martens[ | 2020 | 加拿大 | 26/20 | — | — | tDCS+常规治疗/假刺激+常规治疗 | FL+PL | 4 mA | — | 6 d | CRS-R | — |
| Nekkanti[ | 2016 | 马来西亚 | 10/10 | — | — | MNES+常规治疗/常规治疗 | 正中神经 | 20 mA | 40 | 1 m | GCS | 1 m |
| Sun[ | 2023 | 中国 | 39/39 | 56.49±8.56/ 55.33±9.63 | (22.12±8.35)d/(21.85±7.41)d | tDCS+常规治疗/常规治疗 | DLPFC | 2 mA | — | 8 w | GCS | 8 w |
| Thibaut[ | 2023 | 比利时 | 33/29 | — | — | tDCS+常规治疗/假刺激+常规治疗 | DLPFC | 2 mA | — | 4 w | CRS-R | — |
| Xu[ | 2023 | 中国 | 10/10 | — | — | HF-rTMS+常规治疗/假刺激+常规治疗 | PPC | 90%RMT | 10 | 10 d | CRS-R | — |
| Xu[ | 2024 | 中国 | 10/10 | — | — | HF-rTMS+常规治疗/假刺激+常规治疗 | DLPFC | 90%RMT | 10 | 10 d | CRS-R | — |
| Zhou[ | 2023 | 中国 | 25/25 | 54.03±12.18/ 53.74±12.10 | (55.15±44.81)d/(39.55±23.97)d | ta-VNS+常规治疗/假刺激+常规治疗 | 左耳耳屏 | — | 20 | 4 w | CRS-R、GCS | 8 w |
| 曾淑娟[ | 2023 | 中国 | 22/20 | 43.14±2.81/ 43.60±3.07 | (5.25±0.51)m/(5.12±0.52)m | HF-rTMS+药物治疗/假刺激+药物治疗 | TPJ | 100%RMT | 10 | 2 w | CRS-R | — |
| 陈擘璨[ | 2021 | 中国 | 80/80 | 56.16±10.56/ 54.25±10.30 | (5.33±2.40)m/(5.44±2.16)m | HF-rTMS+常规治疗/常规治疗 | DLPFC | 80%RMT | 20 | 3 m | GCS | — |
| 陈冬艳[ | 2024 | 中国 | 44/44 | — | — | HF-rTMS+常规治疗/常规治疗 | DLPFC | 110%RMT | 5 | 4 w | CRS-R、GCS | — |
| 陈荣[ | 2014 | 中国 | 30/30 | 61.73±5.07/ 60.90±4.72 | — | MNES+常规治疗/常规治疗 | 正中神经 | 15~20 mA | 50~150 | 4 w | GCS | — |
| 程晓午[ | 2021 | 中国 | 30/30 | 52.11±8.50/ 52.03±8.93 | (4.3±1.6)m/(4.3±1.5)m | MNES+常规治疗/常规治疗 | 正中神经 | 10~20 mA | 40 | 21 d | GCS | — |
| 程杨玉[ | 2023 | 中国 | 61/61 | 39.57±9.51/ 40.49±9.26 | — | MNES+常规治疗/常规治疗 | 正中神经 | — | 40 | 10 d | GCS | — |
| 池林[ | 2018 | 中国 | 19/19 | 42.68±14.81/ 45.37±13.04 | (29.63±4.69)d/(27.42±4.69)d | tDCS+常规治疗/常规治疗 | DLPFC | 2 mA | — | 20 d | GCS | — |
| 丁锦荣[ | 2018 | 中国 | 50/50 | — | — | MNES+常规治疗/常规治疗 | 正中神经点 | 20 mA | 40 | 3 m | GCS | — |
| 封苏平[ | 2008 | 中国 | 20/20 | 36.12±10.31/ 34.56±9.33 | — | MNES+常规治疗/常规治疗 | 正中神经点 | 20 mA | 40 | 4 w | GCS | — |
| 冯枫[ | 2020 | 中国 | 25/25 | 50.75±4.51/ 51.23±4.77 | — | tDCS+常规治疗/常规治疗 | DLPFC | 1~2 mA | — | 40 d | CRS-R | |
| 郭静[ | 2021 | 中国 | 57/56 | 45.12±4.22/ 44.71±4.63 | — | tDCS+常规治疗/常规治疗 | DLPFC | 1.4 mA | — | 4 w | GCS | — |
| 洪盈盈[ | 2022 | 中国 | 40/39 | 52.69±3.64/ 52.47±3.58 | — | tDCS+常规治疗/常规治疗 | DLPFC | 1~2 mA | — | 20 d | CRS-R | — |
| 第一作者 | 时间(年) | 国家 | 样本量(T/C)(例) | 平均年龄(T/C) ( | 平均病程(T/C) | 干预措施(T/C) | 刺激部位 | 刺激强度 | 刺激频率(Hz) | 干预时间 | 结局指标 | 随访时间 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 化龙昂[ | 2025 | 中国 | 22/20 | 42.75±10.59/ 44.64±10.08 | (126.12±59.83)d/(136.55±62.26)d | ta-VNS治疗+针刺/针刺 | 左耳耳屏 | 6 mA | 20 | 4 w | CRS-R、GCS | — |
| 黄静[ | 2025 | 中国 | 43/43 | 50.53±12.61/ 54.77±11.04 | — | MNES+常规治疗/常规治疗 | 正中神经点 | — | 50 | 3 m | CRS-R、GCS | — |
| 黄强[ | 2011 | 中国 | 28/28 | 44.70±11.30/ 43.30±10.9 | — | MNES+常规治疗/常规治疗 | 正中神经点 | — | 40 | 4 w | GCS | — |
| 兰东[ | 2024 | 中国 | 39/39 | 43.26±9.68/ 40.87±11.34 | — | MNES+常规治疗/常规治疗 | 正中神经点 | 20 mA | 40 | 4 w | GCS | — |
| 雷彪[ | 2024 | 中国 | 34/34 | 60.47±9.81/ 60.18±8.85 | (53.37±30.57)d/(55.68±20.89)d | ta-VNS治疗+常规治疗/常规治疗 | 左耳耳屏 | 4~6 mA | 20 | 4 w | CRS-R | — |
| 李坤彬[ | 2016 | 中国 | 50/50 | 64.2±5.70/ 66.8±6.90 | — | HF-rTMS+常规治疗/常规治疗 | DLPFC | 110%RMT | 20 | 1 m | GCS | — |
| 李亚利[ | 2021 | 中国 | 40/40 | 30.42±5.04/ 30.59±4.52 | (44.55±3.34)d/(43.82±3.86)d | HF-rTMS+常规治疗/假刺激+常规治疗 | M1 | 90%RMT | 3 | 4 w | CRS-R、GCS | — |
| 梁文海[ | 2016 | 中国 | 46/43 | 48.43±8.28/ 47.95±8.03 | (15.31±3.83)w/(14.02±3.89)w | MNES+常规治疗/常规治疗 | 正中神经 | 20~30 mA | 50 | 1 m | GCS | — |
| 马亮[ | 2022 | 中国 | 25/25 | 36.01±5.98/ 35.89±6.37 | — | HF-rTMS+醒脑静注射液/醒脑静注射液 | M1 | 80%RMT | 20 | 4 w | CRS-R、GCS | — |
| 潘思忆[ | 2024 | 中国 | 41/41 | 51.20±8.40/ 51.30±9.00 | (6.33±0.83)m/(6.25±0.70)m | HF-rTMS+常规治疗/常规治疗 | DLPFC | 80%RMT | 20 | 12 w | CRS-R、GCS | 6 m |
| 潘亚茹[ | 2024 | 中国 | 60/100 | 62.27±5.54/ 61.59±5.19 | (121.74±32.17)d/(115.35±28.46)d | TBS+常规治疗/常规治疗 | DLPFC | 80%RMT | 5 | 1 m | GCS | — |
| 沈龙彬[ | 2019 | 中国 | 28/28 | 33.2±10.15/ 34.7±11.84 | (46.6±2.46)d/(49.5±1.76)d | HF-rTMS+常规治疗/常规治疗 | M1 | 90%RMT | 20 | 20 d | CRS-R、GCS | — |
| 陶敏[ | 2019 | 中国 | 41/41 | 58.10±2.30 | 59.30±2.80 | MNES+常规治疗/常规治疗 | 正中神经 | — | 50 | 4 w | GCS | — |
| 田玲玲[ | 2024 | 中国 | 30/30 | 70.00±3.76/ 71.33±3.27 | (54.63±15.58)d/(56.03±12.89)d | MNES+常规治疗/常规治疗 | 正中神经 | — | 50 | 3 m | CRS-R、GCS | — |
| 王莎[ | 2022 | 中国 | 20/20 | 44.04±4.32/ 44.07±4.34 | — | MNES+常规治疗/常规治疗 | 正中神经 | 20 mA | 40 | 4 w | GCS | — |
| 王诗颖[ | 2023 | 中国 | 45/45 | 43.2±10.70/ 42.8±10.40 | (7.1±2.2)w/(7.4±2.3)w | tDCS+常规治疗/常规治疗 | DLPFC | 1.4 mA | — | 8 w | CRS-R、GCS | — |
| 谢瑛[ | 2011 | 中国 | 15/15 | 55.01±6.83/ 53.97±7.01 | (33.15±2.65)d/(31.86±3.17)d | HF-rTMS+常规治疗/常规治疗 | PFC | 90%RMT | 5 | 1 m | CRS-R、GCS | — |
| 薛亮[ | 2021 | 中国 | 42/41 | 42.3±14.45/ 39.7±13.10 | — | MNES+常规治疗/常规治疗 | 正中神经 | 20 mA | 40 | 2 w | GCS | — |
| 杨初燕[ | 2016 | 中国 | 30/30 | 36.72±12.53/ 35.34±11.11 | (25.75±1.98)d/(25.66±2.12)d | MNES+常规治疗/常规治疗 | 正中神经 | 10~20 mA | 50 | 4 w | GCS | — |
| 余慧敏[ | 2022 | 中国 | 32/32 | 41.25±3.71/ 42.54±3.69 | (2.58±0.17)m/(2.54±0.11)m | ta-VNS治疗+常规治疗/常规治疗 | 左耳耳屏 | 6 mA | — | 4 w | CRS-R、GCS | 2 w |
| 张丽丽[ | 2025 | 中国 | 28/27 | 44.36±2.67/ 45.23±2.43 | (2.54±0.69)m/(2.78±0.53)m | ta-VNS治疗+常规治疗/假刺激+常规治疗 | 耳甲腔 | 2 mA | 4~20 | 8 w | CRS-R、GCS | 12 w |
| 周青[ | 2024 | 中国 | 46/46 | 61.26±6.08/ 62.90±7.10 | (43.69±9.36)d/(41.83±10.03)d | HF-rTMS+常规治疗/常规治疗 | M1 | 90%RMT | 5 | 2 m | CRS-R、GCS | — |
| 第一作者 | 时间(年) | 国家 | 样本量(T/C)(例) | 平均年龄(T/C) ( | 平均病程(T/C) | 干预措施(T/C) | 刺激部位 | 刺激强度 | 刺激频率(Hz) | 干预时间 | 结局指标 | 随访时间 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 化龙昂[ | 2025 | 中国 | 22/20 | 42.75±10.59/ 44.64±10.08 | (126.12±59.83)d/(136.55±62.26)d | ta-VNS治疗+针刺/针刺 | 左耳耳屏 | 6 mA | 20 | 4 w | CRS-R、GCS | — |
| 黄静[ | 2025 | 中国 | 43/43 | 50.53±12.61/ 54.77±11.04 | — | MNES+常规治疗/常规治疗 | 正中神经点 | — | 50 | 3 m | CRS-R、GCS | — |
| 黄强[ | 2011 | 中国 | 28/28 | 44.70±11.30/ 43.30±10.9 | — | MNES+常规治疗/常规治疗 | 正中神经点 | — | 40 | 4 w | GCS | — |
| 兰东[ | 2024 | 中国 | 39/39 | 43.26±9.68/ 40.87±11.34 | — | MNES+常规治疗/常规治疗 | 正中神经点 | 20 mA | 40 | 4 w | GCS | — |
| 雷彪[ | 2024 | 中国 | 34/34 | 60.47±9.81/ 60.18±8.85 | (53.37±30.57)d/(55.68±20.89)d | ta-VNS治疗+常规治疗/常规治疗 | 左耳耳屏 | 4~6 mA | 20 | 4 w | CRS-R | — |
| 李坤彬[ | 2016 | 中国 | 50/50 | 64.2±5.70/ 66.8±6.90 | — | HF-rTMS+常规治疗/常规治疗 | DLPFC | 110%RMT | 20 | 1 m | GCS | — |
| 李亚利[ | 2021 | 中国 | 40/40 | 30.42±5.04/ 30.59±4.52 | (44.55±3.34)d/(43.82±3.86)d | HF-rTMS+常规治疗/假刺激+常规治疗 | M1 | 90%RMT | 3 | 4 w | CRS-R、GCS | — |
| 梁文海[ | 2016 | 中国 | 46/43 | 48.43±8.28/ 47.95±8.03 | (15.31±3.83)w/(14.02±3.89)w | MNES+常规治疗/常规治疗 | 正中神经 | 20~30 mA | 50 | 1 m | GCS | — |
| 马亮[ | 2022 | 中国 | 25/25 | 36.01±5.98/ 35.89±6.37 | — | HF-rTMS+醒脑静注射液/醒脑静注射液 | M1 | 80%RMT | 20 | 4 w | CRS-R、GCS | — |
| 潘思忆[ | 2024 | 中国 | 41/41 | 51.20±8.40/ 51.30±9.00 | (6.33±0.83)m/(6.25±0.70)m | HF-rTMS+常规治疗/常规治疗 | DLPFC | 80%RMT | 20 | 12 w | CRS-R、GCS | 6 m |
| 潘亚茹[ | 2024 | 中国 | 60/100 | 62.27±5.54/ 61.59±5.19 | (121.74±32.17)d/(115.35±28.46)d | TBS+常规治疗/常规治疗 | DLPFC | 80%RMT | 5 | 1 m | GCS | — |
| 沈龙彬[ | 2019 | 中国 | 28/28 | 33.2±10.15/ 34.7±11.84 | (46.6±2.46)d/(49.5±1.76)d | HF-rTMS+常规治疗/常规治疗 | M1 | 90%RMT | 20 | 20 d | CRS-R、GCS | — |
| 陶敏[ | 2019 | 中国 | 41/41 | 58.10±2.30 | 59.30±2.80 | MNES+常规治疗/常规治疗 | 正中神经 | — | 50 | 4 w | GCS | — |
| 田玲玲[ | 2024 | 中国 | 30/30 | 70.00±3.76/ 71.33±3.27 | (54.63±15.58)d/(56.03±12.89)d | MNES+常规治疗/常规治疗 | 正中神经 | — | 50 | 3 m | CRS-R、GCS | — |
| 王莎[ | 2022 | 中国 | 20/20 | 44.04±4.32/ 44.07±4.34 | — | MNES+常规治疗/常规治疗 | 正中神经 | 20 mA | 40 | 4 w | GCS | — |
| 王诗颖[ | 2023 | 中国 | 45/45 | 43.2±10.70/ 42.8±10.40 | (7.1±2.2)w/(7.4±2.3)w | tDCS+常规治疗/常规治疗 | DLPFC | 1.4 mA | — | 8 w | CRS-R、GCS | — |
| 谢瑛[ | 2011 | 中国 | 15/15 | 55.01±6.83/ 53.97±7.01 | (33.15±2.65)d/(31.86±3.17)d | HF-rTMS+常规治疗/常规治疗 | PFC | 90%RMT | 5 | 1 m | CRS-R、GCS | — |
| 薛亮[ | 2021 | 中国 | 42/41 | 42.3±14.45/ 39.7±13.10 | — | MNES+常规治疗/常规治疗 | 正中神经 | 20 mA | 40 | 2 w | GCS | — |
| 杨初燕[ | 2016 | 中国 | 30/30 | 36.72±12.53/ 35.34±11.11 | (25.75±1.98)d/(25.66±2.12)d | MNES+常规治疗/常规治疗 | 正中神经 | 10~20 mA | 50 | 4 w | GCS | — |
| 余慧敏[ | 2022 | 中国 | 32/32 | 41.25±3.71/ 42.54±3.69 | (2.58±0.17)m/(2.54±0.11)m | ta-VNS治疗+常规治疗/常规治疗 | 左耳耳屏 | 6 mA | — | 4 w | CRS-R、GCS | 2 w |
| 张丽丽[ | 2025 | 中国 | 28/27 | 44.36±2.67/ 45.23±2.43 | (2.54±0.69)m/(2.78±0.53)m | ta-VNS治疗+常规治疗/假刺激+常规治疗 | 耳甲腔 | 2 mA | 4~20 | 8 w | CRS-R、GCS | 12 w |
| 周青[ | 2024 | 中国 | 46/46 | 61.26±6.08/ 62.90±7.10 | (43.69±9.36)d/(41.83±10.03)d | HF-rTMS+常规治疗/常规治疗 | M1 | 90%RMT | 5 | 2 m | CRS-R、GCS | — |
| 亚组项目 | 纳入研究数量(篇) | 异质性检验结果 | 效应模型 | Meta分析结果 | ||
|---|---|---|---|---|---|---|
| P值 | I2值(%) | SMD值(95%CI) | P值 | |||
| CRS-R评分 | 29 | <0.001 | 75.7 | 随机效应模型 | 1.06(0.83~1.20) | <0.001 |
| HF-rTMS-DLPFC | 6 | 0.031 | 48.7 | 随机效应模型 | 1.11(0.73~1.49) | <0.001 |
| HF-rTMS-M1 | 4 | 0.012 | 46.3 | 随机效应模型 | 1.49(1.01~2.03) | <0.001 |
| MNES | 2 | 0.035 | 39.7 | 随机效应模型 | 1.08(0.44~1.72) | 0.001 |
| ta-VNS | 5 | 0.026 | 53.7 | 随机效应模型 | 0.90(0.49~1.30) | <0.001 |
| tDCS-DLPFC | 6 | <0.001 | 37.8 | 随机效应模型 | 1.34(0.59~2.09) | <0.001 |
| tDCS-FL+PL | 1 | 0.03(-0.56~0.60) | 0.931 | |||
| HF-rTMS-PFC | 1 | 0.92(0.16~1.67) | 0.017 | |||
| HF-rTMS-PL | 1 | 0.78(-0.13~1.70) | 0.092 | |||
| HF-rTMS-PPC | 1 | 0.28(-0.60~1.16) | 0.534 | |||
| HF-rTMS-TPJ | 1 | 0.42(-0.19~1.03) | 0.181 | |||
| iTBS-CR | 1 | 0.18(-0.41~0.77) | 0.553 | |||
Table 3 Direct meta-analysis results for CRS-R scores
| 亚组项目 | 纳入研究数量(篇) | 异质性检验结果 | 效应模型 | Meta分析结果 | ||
|---|---|---|---|---|---|---|
| P值 | I2值(%) | SMD值(95%CI) | P值 | |||
| CRS-R评分 | 29 | <0.001 | 75.7 | 随机效应模型 | 1.06(0.83~1.20) | <0.001 |
| HF-rTMS-DLPFC | 6 | 0.031 | 48.7 | 随机效应模型 | 1.11(0.73~1.49) | <0.001 |
| HF-rTMS-M1 | 4 | 0.012 | 46.3 | 随机效应模型 | 1.49(1.01~2.03) | <0.001 |
| MNES | 2 | 0.035 | 39.7 | 随机效应模型 | 1.08(0.44~1.72) | 0.001 |
| ta-VNS | 5 | 0.026 | 53.7 | 随机效应模型 | 0.90(0.49~1.30) | <0.001 |
| tDCS-DLPFC | 6 | <0.001 | 37.8 | 随机效应模型 | 1.34(0.59~2.09) | <0.001 |
| tDCS-FL+PL | 1 | 0.03(-0.56~0.60) | 0.931 | |||
| HF-rTMS-PFC | 1 | 0.92(0.16~1.67) | 0.017 | |||
| HF-rTMS-PL | 1 | 0.78(-0.13~1.70) | 0.092 | |||
| HF-rTMS-PPC | 1 | 0.28(-0.60~1.16) | 0.534 | |||
| HF-rTMS-TPJ | 1 | 0.42(-0.19~1.03) | 0.181 | |||
| iTBS-CR | 1 | 0.18(-0.41~0.77) | 0.553 | |||
| 亚组项目 | 纳入研究数量(篇) | 异质性检验结果 | 效应模型 | Meta分析结果 | ||
|---|---|---|---|---|---|---|
| P值 | I2值(%) | SMD值(95%CI) | P值 | |||
| GCS评分 | 36 | <0.001 | 79.6 | 随机效应模型 | 1.23(1.04~1.42) | <0.001 |
| HF-rTMS-DLPFC | 6 | 0.001 | 55.3 | 随机效应模型 | 1.08(0.69~1.46) | <0.001 |
| HF-rTMS-M1 | 4 | <0.001 | 49.4 | 随机效应模型 | 1.57(0.81~2.32) | <0.001 |
| MNES | 15 | <0.001 | 35.7 | 随机效应模型 | 1.13(0.66~1.40) | <0.001 |
| ta-VNS | 5 | <0.001 | 46.4 | 随机效应模型 | 1.68(0.92~2.43) | <0.001 |
| tDCS-DLPFC | 4 | 0.021 | 38.7 | 随机效应模型 | 1.00(0.57~1.43) | <0.001 |
| HF-rTMS-PFC | 1 | 0.50(-0.23~1.23) | 0.178 | |||
| TBS-DLPFC | 1 | 1.50(1.14~1.86) | <0.001 | |||
Table 4 Direct meta-analysis results for GCS scores
| 亚组项目 | 纳入研究数量(篇) | 异质性检验结果 | 效应模型 | Meta分析结果 | ||
|---|---|---|---|---|---|---|
| P值 | I2值(%) | SMD值(95%CI) | P值 | |||
| GCS评分 | 36 | <0.001 | 79.6 | 随机效应模型 | 1.23(1.04~1.42) | <0.001 |
| HF-rTMS-DLPFC | 6 | 0.001 | 55.3 | 随机效应模型 | 1.08(0.69~1.46) | <0.001 |
| HF-rTMS-M1 | 4 | <0.001 | 49.4 | 随机效应模型 | 1.57(0.81~2.32) | <0.001 |
| MNES | 15 | <0.001 | 35.7 | 随机效应模型 | 1.13(0.66~1.40) | <0.001 |
| ta-VNS | 5 | <0.001 | 46.4 | 随机效应模型 | 1.68(0.92~2.43) | <0.001 |
| tDCS-DLPFC | 4 | 0.021 | 38.7 | 随机效应模型 | 1.00(0.57~1.43) | <0.001 |
| HF-rTMS-PFC | 1 | 0.50(-0.23~1.23) | 0.178 | |||
| TBS-DLPFC | 1 | 1.50(1.14~1.86) | <0.001 | |||
| 干预措施 | tDCS-DLPFC | HF-tTMS-DLPFC | HF-tTMS-M1 | ta-VNS | MNES | HF-tTMS-PL | HF-tTMS-PFC | HF-tTMS-TPJ | HF-tTMS-PPC | iTBS-CR | tDCS-FL+PL |
|---|---|---|---|---|---|---|---|---|---|---|---|
| HF-tTMS-DLPFC | 0.24(-0.88~1.35) | ||||||||||
| HF-tTMS-M1 | 0.54(-0.41~1.57) | 0.29(-0.67~1.28) | |||||||||
| ta-VNS | 0.63(-0.55~1.80) | 0.39(-0.79~1.56) | 0.06(-1.06~1.17) | ||||||||
| MNES | 0.70(-0.73~2.13) | 0.46(-0.97~1.89) | 0.13(-1.25~1.50) | 0.07(-1.39~1.54) | |||||||
| HF-tTMS-PL | 1.52(-0.78~3.81) | 1.28(-1.02~3.57) | 0.95(-1.32~3.21) | 0.89(-1.43~3.21) | 0.82(-1.64~3.28) | ||||||
| HF-tTMS-PFC | 1.50(-0.47~3.47) | 1.26(-0.71~3.23) | 0.93(-1.01~2.86) | 0.87(-1.13~2.87) | 0.80(-1.35~2.95) | -0.02(-2.83~2.79) | |||||
| HF-tTMS-TPJ | 1.98(-1.80~4.14) | 1.74(-0.42~3.90) | 1.41(-0.72~3.54) | 1.35(-0.84~3.54) | 1.28(-1.05~3.61) | 0.46(-2.48~3.40) | 0.48(-2.22~1.18) | ||||
| HF-tTMS-PPC | 2.35(-0.26~4.95) | 2.11(-0.49~4.71) | 1.78(-0.80~4.35) | 1.72(-0.91~4.34) | 1.65(-1.10~4.39) | 0.83(-2.45~4.11) | 0.85(-2.21~3.91) | 0.37(-2.82~3.56) | |||
| iTBS-CR | 2.65(0.69~4.60) | 2.41(0.46~4.36) | 2.08(0.16~4.00) | 2.02(0.04~4.00) | 1.95(-0.19~4.09) | 1.13(-1.67~3.93) | 1.15(-1.39~3.69) | 0.67(-2.02~3.36) | 0.30(-2.75~3.35) | ||
| tDCS-FL+PL | 2.92(0.38~5.46) | 2.68(0.14~5.22) | 2.35(-0.17~4.86) | 2.29(-0.28~4.85) | 2.22(-0.47~4.91) | 1.40(-1.84~4.64) | 1.42(-1.59~4.43) | 0.94(-2.20~4.08) | 0.57(-2.89~4.03) | 0.27(-2.73~3.27) | |
| 对照组 | 3.01(2.21~3.80) | 2.77(1.97~3.56) | 2.44(1.73~3.14) | 2.38(1.51~3.25) | 2.31(1.13~3.49) | 1.49(-0.66~3.64) | 1.51(-0.29~3.31) | 1.03(-0.98~3.04) | 0.66(-1.82~3.14) | 0.36(-1.42~2.14) | 0.09(-2.32~2.50) |
Table 5 Results of the network meta-analysis for the CRS-R
| 干预措施 | tDCS-DLPFC | HF-tTMS-DLPFC | HF-tTMS-M1 | ta-VNS | MNES | HF-tTMS-PL | HF-tTMS-PFC | HF-tTMS-TPJ | HF-tTMS-PPC | iTBS-CR | tDCS-FL+PL |
|---|---|---|---|---|---|---|---|---|---|---|---|
| HF-tTMS-DLPFC | 0.24(-0.88~1.35) | ||||||||||
| HF-tTMS-M1 | 0.54(-0.41~1.57) | 0.29(-0.67~1.28) | |||||||||
| ta-VNS | 0.63(-0.55~1.80) | 0.39(-0.79~1.56) | 0.06(-1.06~1.17) | ||||||||
| MNES | 0.70(-0.73~2.13) | 0.46(-0.97~1.89) | 0.13(-1.25~1.50) | 0.07(-1.39~1.54) | |||||||
| HF-tTMS-PL | 1.52(-0.78~3.81) | 1.28(-1.02~3.57) | 0.95(-1.32~3.21) | 0.89(-1.43~3.21) | 0.82(-1.64~3.28) | ||||||
| HF-tTMS-PFC | 1.50(-0.47~3.47) | 1.26(-0.71~3.23) | 0.93(-1.01~2.86) | 0.87(-1.13~2.87) | 0.80(-1.35~2.95) | -0.02(-2.83~2.79) | |||||
| HF-tTMS-TPJ | 1.98(-1.80~4.14) | 1.74(-0.42~3.90) | 1.41(-0.72~3.54) | 1.35(-0.84~3.54) | 1.28(-1.05~3.61) | 0.46(-2.48~3.40) | 0.48(-2.22~1.18) | ||||
| HF-tTMS-PPC | 2.35(-0.26~4.95) | 2.11(-0.49~4.71) | 1.78(-0.80~4.35) | 1.72(-0.91~4.34) | 1.65(-1.10~4.39) | 0.83(-2.45~4.11) | 0.85(-2.21~3.91) | 0.37(-2.82~3.56) | |||
| iTBS-CR | 2.65(0.69~4.60) | 2.41(0.46~4.36) | 2.08(0.16~4.00) | 2.02(0.04~4.00) | 1.95(-0.19~4.09) | 1.13(-1.67~3.93) | 1.15(-1.39~3.69) | 0.67(-2.02~3.36) | 0.30(-2.75~3.35) | ||
| tDCS-FL+PL | 2.92(0.38~5.46) | 2.68(0.14~5.22) | 2.35(-0.17~4.86) | 2.29(-0.28~4.85) | 2.22(-0.47~4.91) | 1.40(-1.84~4.64) | 1.42(-1.59~4.43) | 0.94(-2.20~4.08) | 0.57(-2.89~4.03) | 0.27(-2.73~3.27) | |
| 对照组 | 3.01(2.21~3.80) | 2.77(1.97~3.56) | 2.44(1.73~3.14) | 2.38(1.51~3.25) | 2.31(1.13~3.49) | 1.49(-0.66~3.64) | 1.51(-0.29~3.31) | 1.03(-0.98~3.04) | 0.66(-1.82~3.14) | 0.36(-1.42~2.14) | 0.09(-2.32~2.50) |
| 干预措施 | HF-rTMS-M1 | ta-VNS | HF-rTMS-DLPFC | MNES | tDCS-DLPFC | TBS-DLPFC | HF-rTMS-PFC |
|---|---|---|---|---|---|---|---|
| ta-VNS | 0.48(-0.55~1.51) | ||||||
| HF-rTMS-DLPFC | 0.66(-0.34~1.67) | 0.19(-0.82~1.19) | |||||
| MNES | 0.82(-0.03~1.67) | 0.34(-0.51~1.19) | 0.16(-0.66~0.97) | ||||
| tDCS-DLPFC | 1.42(0.35~2.50) | 0.95(-0.13~2.02) | 0.76(-0.29~1.81) | 0.60(-0.30~1.51) | |||
| TBS-DLPFC | 1.97(0.45~3.59) | 1.57(0.01~3.14) | 1.38(-0.16~2.93) | 1.23(-0.22~2.68) | 0.62(-0.97~2.22) | ||
| HF-rTMS-PFC | 2.08(0.27~4.05) | 1.71(-0.18~3.60) | 1.52(-0.35~3.40) | 1.37(-0.43~3.17) | 0.76(-1.15~2.68) | 0.14(-2.09~2.37) | |
| 对照组 | 2.94(2.21~3.67) | 2.46(1.73~3.19) | 2.27(1.58~2.96) | 2.12(1.68~2.55) | 1.51(0.72~2.30) | 0.89(-0.50~2.28) | 0.75(-0.99~2.49) |
Table 6 Results of the network meta-analysis for the CRS-R
| 干预措施 | HF-rTMS-M1 | ta-VNS | HF-rTMS-DLPFC | MNES | tDCS-DLPFC | TBS-DLPFC | HF-rTMS-PFC |
|---|---|---|---|---|---|---|---|
| ta-VNS | 0.48(-0.55~1.51) | ||||||
| HF-rTMS-DLPFC | 0.66(-0.34~1.67) | 0.19(-0.82~1.19) | |||||
| MNES | 0.82(-0.03~1.67) | 0.34(-0.51~1.19) | 0.16(-0.66~0.97) | ||||
| tDCS-DLPFC | 1.42(0.35~2.50) | 0.95(-0.13~2.02) | 0.76(-0.29~1.81) | 0.60(-0.30~1.51) | |||
| TBS-DLPFC | 1.97(0.45~3.59) | 1.57(0.01~3.14) | 1.38(-0.16~2.93) | 1.23(-0.22~2.68) | 0.62(-0.97~2.22) | ||
| HF-rTMS-PFC | 2.08(0.27~4.05) | 1.71(-0.18~3.60) | 1.52(-0.35~3.40) | 1.37(-0.43~3.17) | 0.76(-1.15~2.68) | 0.14(-2.09~2.37) | |
| 对照组 | 2.94(2.21~3.67) | 2.46(1.73~3.19) | 2.27(1.58~2.96) | 2.12(1.68~2.55) | 1.51(0.72~2.30) | 0.89(-0.50~2.28) | 0.75(-0.99~2.49) |
| 结局指标 | 研究数量(篇) | 样本量(例) | 偏倚风险 | 不一致性 | 间接性 | 精确性 | 发表偏倚 | 证据质量 |
|---|---|---|---|---|---|---|---|---|
| CRS-R评分 | 29 | 1 592 | 0 | 0 | 0 | 0 | -1 | 中 |
| GCS评分 | 36 | 2 660 | 0 | 0 | 0 | 0 | -1 | 中 |
Table 7 GRADE evidence grading results
| 结局指标 | 研究数量(篇) | 样本量(例) | 偏倚风险 | 不一致性 | 间接性 | 精确性 | 发表偏倚 | 证据质量 |
|---|---|---|---|---|---|---|---|---|
| CRS-R评分 | 29 | 1 592 | 0 | 0 | 0 | 0 | -1 | 中 |
| GCS评分 | 36 | 2 660 | 0 | 0 | 0 | 0 | -1 | 中 |
| [1] |
|
| [2] |
|
| [3] |
|
| [4] |
|
| [5] |
|
| [6] |
|
| [7] |
|
| [8] |
李庚, 刘双丽, 范硕辰, 等. 基于数据挖掘技术分析针灸治疗脑损伤后意识障碍的选穴规律[J]. 右江民族医学院学报, 2025, 47(1): 149-155. DOI: 10.3969/j.issn.1001-5817.2025.01.025.
|
| [9] |
|
| [10] |
|
| [11] |
|
| [12] |
|
| [13] |
|
| [14] |
|
| [15] |
|
| [16] |
|
| [17] |
|
| [18] |
|
| [19] |
|
| [20] |
|
| [21] |
刘津池, 刘畅, 华成舸. 随机对照试验偏倚风险评价工具RoB2 (2019修订版)解读[J]. 中国循证医学杂志, 2021, 21(6): 737-744. DOI: 10.7507/1672-2531.202011144.
|
| [22] |
|
| [23] |
|
| [24] |
|
| [25] |
|
| [26] |
|
| [27] |
|
| [28] |
|
| [29] |
|
| [30] |
|
| [31] |
|
| [32] |
|
| [33] |
|
| [34] |
|
| [35] |
|
| [36] |
|
| [37] |
曾淑娟, 刘震洋, 牛剑平, 等. 经颅磁刺激干预意识障碍患者颞顶交界区的疗效分析[J]. 临床神经外科杂志, 2023, 20(6): 619-624. DOI: 10.3969/j.issn.1672-7770.2023.06.004.
|
| [38] |
陈擘璨, 陈凌飞, 刘赞. 多感官刺激促醒联合经颅磁治疗对大面积脑梗死患者意识障碍的觉醒效果观察[J]. 中华保健医学杂志, 2021, 23(5): 462-464. DOI: 10.3969/j.issn.1674-3245.2021.05.011.
|
| [39] |
陈冬艳, 齐金芳, 王利勇, 等. 高频重复经颅磁刺激联合高压氧对颅脑损伤后昏迷患者预后、意识障碍程度及血清AQP-1水平的影响[J]. 临床和实验医学杂志, 2024, 23(10): 1086-1090. DOI: 10.3969/j.issn.1671-4695.2024.10.021.
|
| [40] |
陈荣, 卓叶雯. 正中神经电刺激对高血压性脑出血昏迷患者促醒的作用[J]. 齐鲁护理杂志, 2014, 20(5): 65-66. DOI: 10.3969/j.issn.1006-7256.2014.05.031.
|
| [41] |
程晓午. 右正中神经电刺激对颅脑损伤昏迷促醒的效果分析[J]. 中国医药科学, 2021, 11(4): 180-182, 186. DOI: 10.3969/j.issn.2095-0616.2021.04.048.
|
| [42] |
程杨玉, 刘晓东, 秦宝华, 等. 高压氧联合右正中神经电刺激对重型颅脑损伤昏迷病人觉醒时间、血清生物学指标的影响[J]. 中西医结合心脑血管病杂志, 2023, 21(15): 2859-2862. DOI: 10.12102/j.issn.1672-1349.2023.15.030.
|
| [43] |
池林, 李红玲, 赵龙, 等. 经颅直流电刺激对意识障碍患者恢复的影响[J]. 中华物理医学与康复杂志, 2018, 40(9): 652-656. DOI: 10.3760/cma.j.issn.0254-1424.2018.09.004.
|
| [44] |
丁锦荣, 吴德模, 管义祥, 等. 正中神经电刺激对急性颅脑损伤昏迷患者脑血流及促醒效果的影响[J]. 创伤外科杂志, 2018, 20(12): 884-886. DOI: 10.3969/j.issn.1009-4237.2018.12.002.
|
| [45] |
封苏平, 黎萍, 黄强, 等. 右正中神经电刺激对重型脑外伤患者促醒作用的临床观察[J]. 中华物理医学与康复杂志, 2008, 30(5): 327-328. DOI: 10.3321/j.issn:0254-1424.2008.05.010.
|
| [46] |
冯枫, 孙晓龙, 琚芬, 等. 经颅直流电刺激治疗重型颅脑损伤后意识障碍的临床效果及对患者神经功能的影响[J]. 临床医学研究与实践, 2020, 5(15): 7-8, 16. DOI: 10.19347/j.cnki.2096-1413.202015003.
|
| [47] |
郭静, 毛艳艳, 贾换, 等. tDCS联合感知水平唤醒对颅脑损伤意识障碍患者预后的影响[J]. 癫痫与神经电生理学杂志, 2021, 30(5): 263-268. DOI: 10.19984/j.cnki.1674-8972.2021.05.002.
|
| [48] |
洪盈盈, 薛开禄, 邓焕华, 等. 经颅直流电刺激治疗重型颅脑损伤后意识障碍的临床疗效[J]. 吉林医学, 2022, 43(12): 3306-3308. DOI: 10.3969/j.issn.1004-0412.2022.12.047.
|
| [49] |
化龙昂, 赖海芳, 杨威, 等. 耳迷走神经电刺激对慢性意识障碍促醒的效果[J]. 中国康复理论与实践, 2025, 31(3): 339-347. DOI: 10.3969/j.issn.1006-9771.2025.03.011.
|
| [50] |
黄静, 韩文杰, 韩琼佩. 不同脉冲宽度对意识障碍患者促醒效果、诱发电位及颅内血流速度的影响[J]. 中国卫生工程学, 2025, 24(2): 268-270. DOI: 10.19937/j.issn.1671-4199.2025.02.037.
|
| [51] |
黄强, 戴伟民, 揭园庆, 等. 持续右正中神经刺激促进重型颅脑损伤昏迷患者恢复的前瞻性非随机同期病例对照研究[J]. 中国中西医结合急救杂志, 2011, 18(3): 138-141. DOI: 10.3969/j.issn.1008-9691.2011.03.004.
|
| [52] |
兰东, 李乐, 舒能媛, 等. 早期高压氧联合正中神经电刺激治疗重型颅脑损伤的疗效及对患者血流动力学、昏迷程度和神经功能的影响[J]. 新乡医学院学报, 2024, 41(3): 251-256. DOI: 10.7683/xxyxyxb.2024.03.010.
|
| [53] |
雷彪, 王晓峰, 杨若琳, 等. 经皮耳甲迷走神经刺激治疗慢性意识障碍临床观察[J]. 中国实用神经疾病杂志, 2024, 27(5): 552-556. DOI: 10.12083/SYSJ.230843.
|
| [54] |
李坤彬, 姚先丽, 孙平鸽, 等. 运动疗法结合重复经颅磁刺激治疗脑梗死后意识障碍恢复的临床疗效[J]. 中国实用神经疾病杂志, 2016, 19(8): 63-65. DOI: 10.3969/j.issn.1673-5110.2016.08.035.
|
| [55] |
李亚利, 李婧莲, 王东东, 等. 高频重复经颅磁刺激对重症颅脑损伤后意识障碍患者神经电生理及脑脊液兴奋性氨基酸水平的影响[J]. 实用临床医药杂志, 2021, 25(17): 57-60. DOI: 10.7619/jcmp.20211483.
|
| [56] |
梁文海. 右正中神经电刺激治疗颅脑创伤性昏迷的研究[J]. 中国临床新医学, 2016, 9(3): 197-201. DOI: 10.3969/j.issn.1674-3806.2016.03.04.
|
| [57] |
马亮, 毕立杰, 陈婧. 重复经颅磁刺激联合醒脑静注射液对脑损伤后意识障碍患者意识状态及神经功能的影响[J]. 临床医学研究与实践, 2022, 7(33): 43-47. DOI: 10.19347/j.cnki.2096-1413.202233011.
|
| [58] |
潘思忆, 潘蓉蓉, 俞晓露, 等. 多感官刺激疗法联合重复经颅磁刺激对脑损伤后意识障碍的促醒作用[J]. 浙江实用医学, 2024, 29(6): 537-540. DOI: 10.3969/j.issn.1007-3299.2024.06.029.
|
| [59] |
潘亚茹, 黄露露, 蔺灿灿, 等. 爆发式磁刺激联合多感官刺激在中枢神经系统损伤致意识障碍患者中的应用[J]. 黑龙江医药科学, 2024, 47(1): 106-107, 110. DOI: 10.3969/j.issn.1008-0104.2024.01.038.
|
| [60] |
沈龙彬, 欧阳辉, 杨承佑, 等. 高频重复经颅磁刺激对重症颅脑损伤后意识障碍的促醒疗效[J]. 中国康复医学杂志, 2019, 34(12): 1411-1417. DOI: 10.3969/j.issn.1001-1242.2019.12.004.
|
| [61] |
陶敏, 马彦霖, 陈礼娜. 右侧正中神经电刺激对大面积脑梗死意识障碍患者促醒作用的临床观察[J]. 中外医学研究, 2019, 17(4): 135-136. DOI: 10.14033/j.cnki.cfmr.2019.04.065.
|
| [62] |
田玲玲, 谌秘, 邵秀芹, 等. 不同时长正中神经电刺激对意识障碍患者促醒的效果[J]. 实用临床医学, 2024, 25(2): 89-92, 107. DOI: 10.13764/j.cnki.lcsy.2024.02.021.
|
| [63] |
王莎, 张琰, 郝利霞, 等. 正中神经电刺激在昏迷促醒中的应用研究[J]. 现代消化及介入诊疗, 2022, 27(S1): 96-97.
|
| [64] |
王诗颖, 姜吉, 杨正文, 等. 经颅直流电刺激治疗重型颅脑损伤后意识障碍的临床效果观察[J]. 医学食疗与健康, 2023, 21(29): 54-55, 76.
|
| [65] |
谢瑛, 蒋燕, 胡玥, 等. 经颅电刺激小脑顶核对脑损伤后意识障碍患者脑血流速度及神经电生理的影响[J]. 中国医药导报, 2011, 8(35): 51-53. DOI: 10.3969/j.issn.1673-7210.2011.35.023.
|
| [66] |
薛亮, 汪熙臻, 陈业煌, 等. 正中神经电刺激对NICU重型颅脑损伤昏迷促醒的临床研究[J]. 中华神经创伤外科电子杂志, 2021, 7(1): 17-20. DOI: 10.3877/cma.j.issn.2095-9141.2021.01.004.
|
| [67] |
杨初燕, 王亮, 冯珍, 等. 正中神经电刺激对脑外伤后昏迷患者促醒作用的临床及机制研究[J]. 中国康复医学杂志, 2016, 31(11): 1195-1199, 1207. DOI: 10.3969/j.issn.1001-1242.2016.11.004.
|
| [68] |
余慧敏. 迷走神经电刺激治疗创伤性脑损伤慢性意识障碍的效果观察[J]. 中外医药研究, 2022, 1(6): 60-62. DOI: 10.3969/j.issn.2096-6229.2022.06.020.
|
| [69] |
张丽丽, 王肃馨, 王立峰, 等. 经皮耳迷走神经电刺激联合多感官情景刺激对持续性植物状态患者的促醒效果研究[J]. 实用临床医药杂志, 2025, 29(1): 23-27. DOI: 10.7619/jcmp.20242765.
|
| [70] |
周青, 孙娟. hrTMS联合MSS在重型颅脑损伤后慢性意识障碍患者的应用效果分析[J]. 重庆医学, 2024, 53(1): 93-97. DOI: 10.3969/j.issn.1671-8348.2024.01.019.
|
| [71] |
|
| [72] |
|
| [73] |
|
| [74] |
胡东洋, 韩晓琛, 姚生, 等. 五种昏迷评估量表对重症卒中患者预后预测效能的对比研究[J]. 中国脑血管病杂志, 2025, 22(1): 15-22, 37. DOI: 10.3969/j.issn.1672-5921.2025.01.003.
|
| [75] |
|
| [76] |
|
| [77] |
|
| [78] |
|
| [79] |
林友益, 陈善佳, 宋海燕. 颅脑损伤后意识障碍的无创神经调控治疗进展[J]. 中国实用神经疾病杂志, 2020, 23(10): 917-920. DOI: 10.12083/SYSJ.2020.10.192.
|
| [80] |
|
| [81] |
|
| [1] | ZHAO Congjuan, JIN Tiantian, LIANG Jie, WANG Beining, GAO Yan. Comparative Effectiveness of GLP-1 Receptor Agonists on Patients with Diabetic Kidney Disease: a Network Meta-analysis [J]. Chinese General Practice, 2026, 29(29): 4326-4336. |
| [2] | JIANG Yanlin, WANG Zhe, ZHAI Rui, ZHANG Mengjie, CHEN Xi, WANG Junhong. Screening Optimal Traditional Chinese Medicine Compound Formulas for ADHD Treatment: a Study Integrating Network Meta-analysis and Entropy-weighted TOPSIS Method [J]. Chinese General Practice, 2026, 29(27): 3985-3994. |
| [3] | LI Yutong, ZHAO Danting, JIANG Feng, WANG Yanna, LIU Yizong, LIANG Wenjuan, LU Jiahai. Systematic Review and Meta-analysis of the Efficacy and Safety of mRNA and Recombinant Protein Subunit Vaccines Against Respiratory Syncytial Virus [J]. Chinese General Practice, 2026, 29(19): 2744-2752. |
| [4] | WANG Fei, HAN Weiyu, SUN Tao. Moxibustion Combined with Three-step Therapy in the Treatment of Cancer Pain: a Network Meta-analysis [J]. Chinese General Practice, 2026, 29(09): 1203-1211. |
| [5] | ZHANG Ling, HUANG Shuangying, XU Hui, MEI Huiting, HONG Yongping. Effects of Different Exercise Types on Fall Efficacy in the Elderly: a Network Meta-analysis [J]. Chinese General Practice, 2026, 29(06): 741-751. |
| [6] | Expert Panel of the National Key R&D Program "Research on the Effects and Mechanisms of Multiple Types of Physical Stimulation on Body Function", Brain Function Detection and Regulation Rehabilitation Professional Committee of Chinese Association of Rehabilitation Medicine, Cerebral Small Vessel Disease Professional Committee of Beijing Neurology Association. Expert Consensus on the Effects and Efficacy Evaluation of Non-invasive Neuromodulation in Elders with Disability and Dementia [J]. Chinese General Practice, 2025, 28(34): 4258-4281. |
| [7] | QUAN Jialin, ZHU Lin, SU Yu, CHEN Zekai, CHEN Ziqi, ZHANG Zhuofan. Research on the Improvement Effect of Exercise Modes on the Executive Function of Overweight or Obese Children or Adolescents: a Network Meta-analysis [J]. Chinese General Practice, 2025, 28(27): 3422-3431. |
| [8] | LI Hao, LI Jiangtao, LIU Dan, WANG Jianjun. Efficacy and Safety of Belimumab, Anifrolumab, and Telitacicept on the Treatment of Systemic Lupus Erythematosus: a Network Meta-analysis [J]. Chinese General Practice, 2025, 28(23): 2924-2933. |
| [9] | ZHU Shengjie, DIAO Huaqiong, HANG Xiaoyi, SUN Wenjun. Network Meta-analysis of Different Traditional Chinese Medicine Injections for the Treatment of Posterior Circulatory Ischemic Vertigo [J]. Chinese General Practice, 2025, 28(14): 1795-1808. |
| [10] | CHI Xun, LIU Sisi, CHEN Qiao, HU Yue, WANG Weixian. The Suitability of Four Nutritional Screening Tools for Nutritional Screening in Patients with Cirrhosis: a Network Meta-analysis [J]. Chinese General Practice, 2025, 28(11): 1395-1402. |
| [11] | GU Mingyu, QIN Tingting, QIAO Kun, BAI Xinyuan, WANG Yao, YANG Yutong, LI Xingming. A Network Meta-analysis of Primary Hypertension Management Patterns in China [J]. Chinese General Practice, 2025, 28(10): 1265-1272. |
| [12] | GUO Jia, CAO Chunmei, LIU Guochun, ZHENG Man, ZHU Ruihan, LONG Wei. Effects of Different Exercise Types on Sleep in Insomnia Patients: a Network Meta-analysis [J]. Chinese General Practice, 2024, 27(35): 4376-4387. |
| [13] | ZHANG Huimin, SHAN Dawei, ZHANG Yan. Perspectives on the Application of Neural Oscillations in the Diagnosis and Treatment of Consciousness Disorders [J]. Chinese General Practice, 2024, 27(32): 4093-4096. |
| [14] | HUANG Tengjia, CAO Xi, CHEN Lei, LI Ziying, QIN Lihua. The Effectiveness of Non-pharmacological Treatment for Post-stroke Shoulder-hand Syndrome: a Network Meta-analysis [J]. Chinese General Practice, 2024, 27(23): 2921-2930. |
| [15] | WANG Ting, WANG Haiyan, FU Wenjun. Effect of Chronic Atrophic Gastritis Treated with Different Acupuncture and Moxibustion Therapies: a Network Meta-analysis [J]. Chinese General Practice, 2024, 27(23): 2913-2920. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||